138 related articles for article (PubMed ID: 18518845)
1. Pharmacogenomics of importance for paclitaxel chemotherapy.
Green H
Pharmacogenomics; 2008 Jun; 9(6):671-4. PubMed ID: 18518845
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
Steed H; Sawyer MB
Pharmacogenomics; 2007 Jul; 8(7):803-15. PubMed ID: 17638515
[TBL] [Abstract][Full Text] [Related]
3. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
5. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.
de Graan AJ; Elens L; Smid M; Martens JW; Sparreboom A; Nieuweboer AJ; Friberg LE; Elbouazzaoui S; Wiemer EA; van der Holt B; Verweij J; van Schaik RH; Mathijssen RH
Clin Cancer Res; 2013 Sep; 19(18):5210-7. PubMed ID: 23918604
[TBL] [Abstract][Full Text] [Related]
6. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?
Gehrmann M; Schmidt M; Brase JC; Roos P; Hengstler JG
Pharmacogenomics; 2008 Jul; 9(7):969-74. PubMed ID: 18597657
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer response to paclitaxel in vivo.
Symmans FW
Drug Resist Updat; 2001 Oct; 4(5):297-302. PubMed ID: 11991683
[TBL] [Abstract][Full Text] [Related]
8. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
Xing H; Wang S; Weng D; Chen G; Yang X; Zhou J; Xu G; Lu Y; Ma D
Oncol Rep; 2007 Jan; 17(1):117-22. PubMed ID: 17143487
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
10. The pharmacoeconomics of cancer therapies.
Bishop JF; Macarounas-Kirchman K
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of paclitaxel metabolism.
Spratlin J; Sawyer MB
Crit Rev Oncol Hematol; 2007 Mar; 61(3):222-9. PubMed ID: 17092739
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological action of paclitaxel].
Potemski P; Płuzańska A
Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Cowan KH; Moscow JA; Huang H; Zujewski JA; O'Shaughnessy J; Sorrentino B; Hines K; Carter C; Schneider E; Cusack G; Noone M; Dunbar C; Steinberg S; Wilson W; Goldspiel B; Read EJ; Leitman SF; McDonagh K; Chow C; Abati A; Chiang Y; Chang YN; Gottesman MM; Pastan I; Nienhuis A
Clin Cancer Res; 1999 Jul; 5(7):1619-28. PubMed ID: 10430060
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
15. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
16. [Paclitaxel (Taxol)].
Hájek R
Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
18. Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
Tao W; Shi JF; Zhang Q; Xue B; Sun YJ; Li CJ
Biomed Pharmacother; 2013 Apr; 67(3):197-202. PubMed ID: 23478574
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
20. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Yamazaki S; Sekine I; Saijo N
Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
